title: Advanced non-small cell lung cancer in the elderly: effective and well tolerated weekly gemcitabine and cisplatin regimen. A pilot study.
abstract: BACKGROUND
  The frequency of advanced non-small cell lung cancer (NSCLC) increases with age and more effective and less toxic chemotherapy schedules are needed in elderly patients. Cisplatin-based regimens are considered the best treatment for advanced NSCLC, although they produce only a modest advantage in overall survival with considerable toxicity.
  
  
  METHODS
  In the present study the activity and toxicity of a weekly gemcitabine and cisplatin schedule was evaluated in a small group of advanced NSCLC patients aged 68 years or more. Treatment consisted of gemcitabine 1000 mg/m2 i.v. and cisplatin 35 mg/m2 i.v., both given weekly on days 1, 8, 15 followed by 1 week of rest.
  
  
  RESULTS
  Fifteen previously untreated patients entered the study; their median age was 72 years (range 68-76). One hundred and sixteen weekly administrations were delivered. The median dose-intensity was 614.5 mg/m2 per week for gemcitabine (82%) and 21 mg/m2 per week for cisplatin (80%). All the 15 patients were evaluable for response and toxicity. The overall response rate was 40% [95% CI = 16-68%]. The main toxicity was WHO grade III-IV thrombocytopenia that was recorded in 6 patients (40%). Other major toxicities were very low and no treatment-related deaths were reported.
  
  
  CONCLUSIONS
  This schedule appears to be active, to have a favourable toxicity profile and can be considered in advanced NSCLC elderly patients. Of interest, the patients enrolled received high dose intensities of both drugs.
authors.affiliation: Divisione di Oncologia Medica, Ospedale S. Croce, Fano.
authors.forename: P
authors.initials: P
authors.lastname: Lippe
authors.forename: R R
authors.initials: RR
authors.lastname: Silva
authors.forename: L
authors.initials: L
authors.lastname: Giuliodori
authors.forename: M A
authors.initials: MA
authors.lastname: Cancellieri
authors.forename: N
authors.initials: N
authors.lastname: Battelli
authors.forename: C
authors.initials: C
authors.lastname: Massacesi
authors.forename: R
authors.initials: R
authors.lastname: Berardi
authors.forename: R
authors.initials: R
authors.lastname: Bisonni
authors.forename: R
authors.initials: R
authors.lastname: Gesuita
authors.forename: R
authors.initials: R
authors.lastname: Cellerino
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D010865:Pilot Projects; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine